AI Article Synopsis
- - Alzheimer's disease (AD) mainly impacts people aged 65 and older, leading to gradual cognitive and functional decline that disrupts daily activities.
- - The disease is characterized by the presence of amyloid plaques that damage neurons and brain connections, and until 2023, treatments only addressed symptoms without altering the disease's progression.
- - In 2023, the FDA approved Lecanemab and aducanumab, marking the first therapies with the potential to modify the disease, with Lecanemab showing promise in improving cognitive function in patients.
Article Abstract
Alzheimer's disease (AD) is a neurodegenerative disease primarily affecting individuals aged 65 or above. AD leads to progressive cognitive and functional decline, affecting daily life activities. Amyloid plaques are the pathological hallmark of AD, resulting in the loss of neurons and their connections in the brain. For years, patients with AD were treated with pharmacotherapies having only symptomatic effects. Till 2023, no drug was approved for disease-modifying potential. The Food and Drug Administration approved Lecanemab and aducanumab as the first therapy with disease-modifying effects in 2023. Lecanemab has shown efficacy in several trials, with the potential to improve cognition in AD patients. In this article, we will discuss the treatment options for AD, emphasizing the newly approved monoclonal antibodies and their prospects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655160 | PMC |
| http://dx.doi.org/10.7759/cureus.47251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional classification of tauopathy strains reveals the role of protofilament core residues.
Sci Adv
January 2025
Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Distinct tau amyloid assemblies underlie diverse tauopathies but defy rapid classification. Cell and animal experiments indicate tau functions as a prion, as different strains propagated in cells cause unique, transmissible neuropathology after inoculation. Strain amplification requires compatibility of the monomer and amyloid template.
View Article and Find Full Text PDFAmyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease.
Sci Transl Med
January 2025
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.
In Alzheimer's disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. However, the pathophysiological link between Aβ and tau remains unclear, which hinders therapeutic efforts to attenuate Aβ-related tau accumulation. Aβ has been found to trigger neuronal hyperactivity and hyperconnectivity, and preclinical research has shown that tau spreads across connected neurons in an activity-dependent manner.
View Article and Find Full Text PDFDown syndrome, resulting from trisomy of human chromosome 21, is a common form of chromosomal disorder that results in intellectual disability and altered risk of several medical conditions. Individuals with Down syndrome have a greatly increased risk of Alzheimer's disease (DSAD), due to the presence of the APP gene on chromosome 21 that encodes the amyloid-β precursor protein (APP). APP can be processed to generate amyloid-β, which accumulates in plaques in the brains of people who have Alzheimer's disease and is the upstream trigger of disease.
View Article and Find Full Text PDFCerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study.
JAMA Netw Open
January 2025
Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Importance: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels.
Objective: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age.
Design, Setting, And Participants: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]).
Depressive Symptoms and Amyloid Pathology.
JAMA Psychiatry
January 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Importance: Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!